Treatment of dystrophic epidermolysis bullosa with bone marrow non-hematopoeitic stem cells: A randomized controlled trial

Dermatologic Therapy

Volumn 29, Issue 2, 2016, Pages 96-100

  El Darouti, Mohammad ^a   Fawzy, Marwa ^a   Amin, Iman ^a   Abdel Hay, Rania ^a   Hegazy, Rehab ^a   Gabr, Hala ^a   El Maadawi, Zeinab ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

bullous disease; cyclosporine; epidermolysis bullosa; stem cells

Indexed keywords

CYCLOSPORIN; PLACEBO; COLLAGEN TYPE 7; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; BONE MARROW NON HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ELECTRON MICROSCOPY; EPIDERMOLYSIS BULLOSA DYSTROPHICA; FEMALE; FIBROBLAST; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; KERATINOCYTE; MALE; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SKIN BIOPSY; TREATMENT OUTCOME; WOUND HEALING; YOUNG ADULT; ADVERSE EFFECTS; BONE MARROW TRANSPLANTATION; CYTOLOGY; GENETICS; INFANT; MUTATION; PATHOLOGY; PROCEDURES; STEM CELL TRANSPLANTATION;

BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; COLLAGEN TYPE VII; CYCLOSPORINE; DOUBLE-BLIND METHOD; EPIDERMOLYSIS BULLOSA DYSTROPHICA; FEMALE; FIBROBLASTS; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MALE; MUTATION; STEM CELL TRANSPLANTATION; YOUNG ADULT;

EID: 84963502857     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/dth.12305     Document Type: Article

References (12)

1. Varki R, Sadowski S, Uitto J, Pfendner E., Epidermolysis bullosa. II. Type VII collagen mutations and phenotype-genotype correlations in the dystrophic subtypes. J Med Genet 2007: 44: 181-192.
2. Woodley DT, Krueger GG, Jorgensen CM, et al., Normal and gene-corrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII collagen at the basement membrane zone. J Invest Dermatol 2003: 121: 1021-1028.
3. Woodley DT, Remington J, Huang Y, et al., Intravenously injected human fibroblasts home to skin wounds, deliver type VII collagen, and promote wound healing. Mol Ther 2007: 15: 628-635.
4. Herzog SR, Meyer A, Woodley D, Peterson HD., Wound coverage with cultured autologous keratinocytes: use after burn wound excision, including biopsy followup. J Trauma 1988: 28: 195-198.
5. Krueger, GG., Fibroblasts and dermal gene therapy: a minireview. Hum Gene Ther 2000: 11: 2289-2296.
6. Fu X, Fang L, Li X, Cheng B, Sheng Z., Enhanced wound-healing quality with bone marrow mesenchymal stem cells autografting after skin injury. Wound Repair Regen 2006: 14: 325-335.
7. Chino T, Tamai K, Yamazaki T, et al., Bone marrow cell transfer into fetal circulation can ameliorate genetic skin diseases by providing fibroblasts to the skin and inducing immune tolerance. Am J Pathol 2008: 173: 803-814.
8. del-Río E., Prevention of blisters in dystrophic recessive epidermolysis bullosa with cyclosporine. J Am Acad Dermatol 1993: 29: 1038-1039.
9. Badiavas EV, Abedi M, Butmarc J, Butmarc J, Falanga V, Quesenberry P., Participation of bone marrow derived cells in cutaneous wound healing. J Cell Physiol 2003: 196: 245-250.
10. How long do stem cells live? http://phys.org/news/2011-03-stem-cells.html. Accessed August 19, 2014.
11. Reddy AM, Kwak BK, Shim HJ, et al., Functional characterization of mesenchymal stem cells labeled with a novel PVP-coated superparamagnetic iron oxide. Contrast Media Mol Imaging 2009: 4: 118-126.
12. Volpi EV, Bridger JM., FISH glossary: an overview of the fluorescence in situ hybridization technique. Biotechniques 2008: 45: 385-386.